Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

314.41 +6.76 (+2.20%)
Streaming Delayed Price Updated: 3:06 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 Next >
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
From United Therapeutics Corporation
Via Business Wire
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
Exposures Product Safety
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
From United Therapeutics Corporation
Via Business Wire
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill... 
Via FinancialNewsMedia
Exposures Product Safety
United Therapeutics Provides an Update on Its Organ Printing Programs
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces FDA Approval of Tyvaso DPI™
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
From United Therapeutics Corporation
Via Business Wire
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world 
Via Newswire.com
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.